These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38027014)

  • 1. Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS).
    Su S; Wu L; Zhou G; Peng L; Zhao H; Wang X; Li K
    Front Pharmacol; 2023; 14():1225919. PubMed ID: 38027014
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database.
    Peng J; Wang H; Liu Z; Xu ZL; Wang MX; Chen QM; Wu ML; Ren XL; Liang QH; Liu FP; Ban B
    Front Pharmacol; 2022; 13():1017391. PubMed ID: 36339548
    [No Abstract]   [Full Text] [Related]  

  • 3. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
    Zhang S; Wang Y; Qi Z; Tong S; Zhu D
    Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization.
    Huynh-Le MP; Shults RC; Connor MJ; Hattangadi-Gluth JA
    Clin Genitourin Cancer; 2020 Jun; 18(3):192-200.e2. PubMed ID: 31902714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases.
    Liang Q; Liao X; Wu H; Huang Y; Liang T; Li H
    Front Pharmacol; 2024; 15():1431562. PubMed ID: 39144633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals.
    Neha R; Beulah E; Anusha B; Vasista S; Stephy C; Subeesh V
    Int J Clin Pharm; 2020 Apr; 42(2):721-727. PubMed ID: 32270377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database.
    Yang X; Yan Y; Liu S; Wang Z; Feng X
    Front Pharmacol; 2024; 15():1376494. PubMed ID: 38846098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
    Chen W; Cai P; Zou W; Fu Z
    Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.
    Li Z; Guo C; Liu X; Qiu Z; Zhang R
    Front Pharmacol; 2024; 15():1368763. PubMed ID: 38549677
    [No Abstract]   [Full Text] [Related]  

  • 11. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
    Liu W; Du Q; Guo Z; Ye X; Liu J
    Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
    [No Abstract]   [Full Text] [Related]  

  • 12. A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS).
    Tang L; Sun C; Liu W; Wu H; Ding C
    Front Pharmacol; 2024; 15():1362484. PubMed ID: 38384285
    [No Abstract]   [Full Text] [Related]  

  • 13. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis.
    Shin YE; Rojanasarot S; Hincapie AL; Guo JJ
    Sex Med; 2023 Oct; 11(5):qfad059. PubMed ID: 38034088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.
    Jiang T; Su H; Li Y; Wu Y; Ming Y; Li C; Fu R; Feng L; Li Z; Li L; Ni R; Liu Y
    Front Pharmacol; 2022; 13():989032. PubMed ID: 36532784
    [No Abstract]   [Full Text] [Related]  

  • 16. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
    Tian X; Chen L; Gai D; He S; Jiang X; Zhang N
    Front Pharmacol; 2022; 13():851246. PubMed ID: 35401230
    [No Abstract]   [Full Text] [Related]  

  • 17. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
    Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
    Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study.
    Zhuang W; Lu M; Wu Y; Chen Z; Wang M; Wang X; Guan S; Lin W
    Clin Drug Investig; 2023 Dec; 43(12):949-962. PubMed ID: 37995087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study.
    Liu F; Yin G; Xue S; Rehman FU; Liao D; Pan Y
    J Cancer; 2023; 14(17):3275-3284. PubMed ID: 37928419
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
    Chai S; Zhan JL; Zhao LM; Liu XD
    Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.